APO Research
Talk to an analyst

APO RESEARCH · REPORT

Meningococcal Disease Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Meningococcal Disease Drugs Market Outlook and Growth Opportunities 2026

19 December 2025190 pages

Choose your research edition.

Industry ResearchMeningococcal Disease Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Meningococcal Disease Drugs Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Meningococcal Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Meningococcal Disease Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Meningococcal Disease Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Meningococcal Disease Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Meningococcal Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Meningococcal Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Meningococcal Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Meningococcal Disease Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Meningococcal Disease Drugs market include Yiling Pharmaceutical, SSY Group Limited, Apeloa Pharmaceutical Co.,Ltd., Novartis, Merck Sharp & Dohme, Lukang Pharmaceutical Co.,Ltd., Shandong Jincheng Pharmaceutical Group Co.,ltd., Pfizer and North China Pharmaceutical Company Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Meningococcal Disease Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Meningococcal Disease Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Meningococcal Disease Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Meningococcal Disease Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Meningococcal Disease Drugs Segment by Company

Yiling Pharmaceutical

SSY Group Limited

Apeloa Pharmaceutical Co.,Ltd.

Novartis

Merck Sharp & Dohme

Lukang Pharmaceutical Co.,Ltd.

Shandong Jincheng Pharmaceutical Group Co.,ltd.

Pfizer

North China Pharmaceutical Company Ltd.

Hebei Hejia Pharmaceutical Technology Group Co., Ltd

Harbin Pharmaceutical Group Co.,Ltd.

GlaxoSmithKline

Baiyunshan Pharmaceutical

Sanofi Pasteur

Meningococcal Disease Drugs Segment by Type

Injectable

Oral

Meningococcal Disease Drugs Segment by Application

Hospitals

Drugstores

Others

Meningococcal Disease Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Meningococcal Disease Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Meningococcal Disease Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Meningococcal Disease Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Meningococcal Disease Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Disease Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Meningococcal Disease Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Meningococcal Disease Drugs industry.

Chapter 3: Detailed analysis of Meningococcal Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Meningococcal Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Meningococcal Disease Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Meningococcal Disease Drugs Industry Trends Table 2. Meningococcal Disease Drugs Industry Drivers Table 3. Meningococcal Disease Drugs Industry Opportunities and Challenges Table 4. Meningococcal Disease Drugs Industry Restraints Table 5. Global Meningococcal Disease Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Meningococcal Disease Drugs Revenue Share by Company (2021-2026) Table 7. Global Meningococcal Disease Drugs Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Meningococcal Disease Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Meningococcal Disease Drugs Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Meningococcal Disease Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Meningococcal Disease Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Meningococcal Disease Drugs Company, Product Type & Application Table 13. Global Meningococcal Disease Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Meningococcal Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Injectable Table 18. Significant Companies of Oral Table 19. Global Meningococcal Disease Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 20. Global Meningococcal Disease Drugs Sales Volume by Type (2021-2026) & (Tons) Table 21. Global Meningococcal Disease Drugs Sales Volume by Type (2027-2032) & (Tons) Table 22. Global Meningococcal Disease Drugs Sales Volume Share by Type (2021-2026) Table 23. Global Meningococcal Disease Drugs Sales Volume Share by Type (2027-2032) Table 24. Global Meningococcal Disease Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Meningococcal Disease Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Meningococcal Disease Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Meningococcal Disease Drugs Sales Value Share by Type (2021-2026) Table 28. Global Meningococcal Disease Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospitals Table 30. Significant Companies of Drugstores Table 31. Significant Companies of Others Table 32. Global Meningococcal Disease Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 33. Global Meningococcal Disease Drugs Sales Volume by Application (2021-2026) & (Tons) Table 34. Global Meningococcal Disease Drugs Sales Volume by Application (2027-2032) & (Tons) Table 35. Global Meningococcal Disease Drugs Sales Volume Share by Application (2021-2026) Table 36. Global Meningococcal Disease Drugs Sales Volume Share by Application (2027-2032) Table 37. Global Meningococcal Disease Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Meningococcal Disease Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Meningococcal Disease Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Meningococcal Disease Drugs Sales Value Share by Application (2021-2026) Table 41. Global Meningococcal Disease Drugs Sales Value Share by Application (2027-2032) Table 42. Global Meningococcal Disease Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 43. Global Meningococcal Disease Drugs Sales by Region (2021-2026) & (Tons) Table 44. Global Meningococcal Disease Drugs Sales Market Share by Region (2021-2026) Table 45. Global Meningococcal Disease Drugs Sales by Region (2027-2032) & (Tons) Table 46. Global Meningococcal Disease Drugs Sales Market Share by Region (2027-2032) Table 47. Global Meningococcal Disease Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Meningococcal Disease Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Meningococcal Disease Drugs Sales Value Share by Region (2021-2026) Table 50. Global Meningococcal Disease Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Meningococcal Disease Drugs Sales Value Share by Region (2027-2032) Table 52. Global Meningococcal Disease Drugs Market Average Price (US$/Ton) by Region (2021-2026) Table 53. Global Meningococcal Disease Drugs Market Average Price (US$/Ton) by Region (2027-2032) Table 54. Global Meningococcal Disease Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 55. Global Meningococcal Disease Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Meningococcal Disease Drugs Sales by Country (2021-2026) & (Tons) Table 57. Global Meningococcal Disease Drugs Sales Market Share by Country (2021-2026) Table 58. Global Meningococcal Disease Drugs Sales by Country (2027-2032) & (Tons) Table 59. Global Meningococcal Disease Drugs Sales Market Share by Country (2027-2032) Table 60. Global Meningococcal Disease Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Meningococcal Disease Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global Meningococcal Disease Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Meningococcal Disease Drugs Sales Value Market Share by Country (2027-2032) Table 64. Yiling Pharmaceutical Company Information Table 65. Yiling Pharmaceutical Business Overview Table 66. Yiling Pharmaceutical Meningococcal Disease Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 67. Yiling Pharmaceutical Meningococcal Disease Drugs Product Portfolio Table 68. Yiling Pharmaceutical Recent Development Table 69. SSY Group Limited Company Information Table 70. SSY Group Limited Business Overview Table 71. SSY Group Limited Meningococcal Disease Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 72. SSY Group Limited Meningococcal Disease Drugs Product Portfolio Table 73. SSY Group Limited Recent Development Table 74. Apeloa Pharmaceutical Co.,Ltd. Company Information Table 75. Apeloa Pharmaceutical Co.,Ltd. Business Overview Table 76. Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 77. Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio Table 78. Apeloa Pharmaceutical Co.,Ltd. Recent Development Table 79. Novartis Company Information Table 80. Novartis Business Overview Table 81. Novartis Meningococcal Disease Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 82. Novartis Meningococcal Disease Drugs Product Portfolio Table 83. Novartis Recent Development Table 84. Merck Sharp & Dohme Company Information Table 85. Merck Sharp & Dohme Business Overview Table 86. Merck Sharp & Dohme Meningococcal Disease Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 87. Merck Sharp & Dohme Meningococcal Disease Drugs Product Portfolio Table 88. Merck Sharp & Dohme Recent Development Table 89. Lukang Pharmaceutical Co.,Ltd. Company Information Table 90. Lukang Pharmaceutical Co.,Ltd. Business Overview Table 91. Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 92. Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio Table 93. Lukang Pharmaceutical Co.,Ltd. Recent Development Table 94. Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information Table 95. Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview Table 96. Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 97. Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Product Portfolio Table 98. Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Development Table 99. Pfizer Company Information Table 100. Pfizer Business Overview Table 101. Pfizer Meningococcal Disease Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 102. Pfizer Meningococcal Disease Drugs Product Portfolio Table 103. Pfizer Recent Development Table 104. North China Pharmaceutical Company Ltd. Company Information Table 105. North China Pharmaceutical Company Ltd. Business Overview Table 106. North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 107. North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Product Portfolio Table 108. North China Pharmaceutical Company Ltd. Recent Development Table 109. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information Table 110. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview Table 111. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 112. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Product Portfolio Table 113. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Development Table 114. Harbin Pharmaceutical Group Co.,Ltd. Company Information Table 115. Harbin Pharmaceutical Group Co.,Ltd. Business Overview Table 116. Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 117. Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Product Portfolio Table 118. Harbin Pharmaceutical Group Co.,Ltd. Recent Development Table 119. GlaxoSmithKline Company Information Table 120. GlaxoSmithKline Business Overview Table 121. GlaxoSmithKline Meningococcal Disease Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 122. GlaxoSmithKline Meningococcal Disease Drugs Product Portfolio Table 123. GlaxoSmithKline Recent Development Table 124. Baiyunshan Pharmaceutical Company Information Table 125. Baiyunshan Pharmaceutical Business Overview Table 126. Baiyunshan Pharmaceutical Meningococcal Disease Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 127. Baiyunshan Pharmaceutical Meningococcal Disease Drugs Product Portfolio Table 128. Baiyunshan Pharmaceutical Recent Development Table 129. Sanofi Pasteur Company Information Table 130. Sanofi Pasteur Business Overview Table 131. Sanofi Pasteur Meningococcal Disease Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 132. Sanofi Pasteur Meningococcal Disease Drugs Product Portfolio Table 133. Sanofi Pasteur Recent Development Table 134. Key Raw Materials Table 135. Raw Materials Key Suppliers Table 136. Meningococcal Disease Drugs Distributors List Table 137. Meningococcal Disease Drugs Customers List Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. Meningococcal Disease Drugs Product Image Figure 2. Global Meningococcal Disease Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Meningococcal Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Meningococcal Disease Drugs Sales (2021-2032) & (Tons) Figure 5. Global Meningococcal Disease Drugs Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Meningococcal Disease Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Injectable Image Figure 10. Oral Image Figure 11. Global Meningococcal Disease Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 12. Global Meningococcal Disease Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Meningococcal Disease Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global Meningococcal Disease Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Meningococcal Disease Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Meningococcal Disease Drugs Sales Value Share by Type (2021-2032) Figure 17. Hospitals Image Figure 18. Drugstores Image Figure 19. Others Image Figure 20. Global Meningococcal Disease Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 21. Global Meningococcal Disease Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Meningococcal Disease Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global Meningococcal Disease Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Meningococcal Disease Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Meningococcal Disease Drugs Sales Value Share by Application (2021-2032) Figure 26. Global Meningococcal Disease Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 27. Global Meningococcal Disease Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Meningococcal Disease Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Meningococcal Disease Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Meningococcal Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America Meningococcal Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Meningococcal Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Meningococcal Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Meningococcal Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Meningococcal Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Meningococcal Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America Meningococcal Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Meningococcal Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Meningococcal Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Meningococcal Disease Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Meningococcal Disease Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Injectable
  • Oral
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Yiling Pharmaceutical
  • SSY Group Limited
  • Apeloa Pharmaceutical Co.,Ltd.
  • Novartis
  • Merck Sharp & Dohme
  • Lukang Pharmaceutical Co.,Ltd.
  • Shandong Jincheng Pharmaceutical Group Co.,ltd.
  • Pfizer
  • North China Pharmaceutical Company Ltd.
  • Hebei Hejia Pharmaceutical Technology Group Co., Ltd
  • Harbin Pharmaceutical Group Co.,Ltd.
  • GlaxoSmithKline
  • Baiyunshan Pharmaceutical
  • Sanofi Pasteur

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Meningococcal Disease Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Meningococcal Disease Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Meningococcal Disease Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Meningococcal Disease Drugs Market Dynamics
  1. 2.1 Meningococcal Disease Drugs Industry Trends
  2. 2.2 Meningococcal Disease Drugs Industry Drivers
  3. 2.3 Meningococcal Disease Drugs Industry Opportunities and Challenges
  4. 2.4 Meningococcal Disease Drugs Industry Restraints
3 Meningococcal Disease Drugs Market by Company
  1. 3.1 Global Meningococcal Disease Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Meningococcal Disease Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Meningococcal Disease Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Meningococcal Disease Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Meningococcal Disease Drugs Company Ranking (2024-2026)
  6. 3.6 Global Meningococcal Disease Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Meningococcal Disease Drugs Company Product Type and Application
  8. 3.8 Global Meningococcal Disease Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Meningococcal Disease Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Meningococcal Disease Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Meningococcal Disease Drugs Market by Type
  1. 4.1 Meningococcal Disease Drugs Type Introduction
  2. 4.1.1 Injectable
  3. 4.1.2 Oral
  4. 4.2 Global Meningococcal Disease Drugs Sales Volume by Type
  5. 4.2.1 Global Meningococcal Disease Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Meningococcal Disease Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Meningococcal Disease Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Meningococcal Disease Drugs Sales Value by Type
  9. 4.3.1 Global Meningococcal Disease Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Meningococcal Disease Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global Meningococcal Disease Drugs Sales Value Share by Type (2021-2032)
5 Meningococcal Disease Drugs Market by Application
  1. 5.1 Meningococcal Disease Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Drugstores
  4. 5.1.3 Others
  5. 5.2 Global Meningococcal Disease Drugs Sales Volume by Application
  6. 5.2.1 Global Meningococcal Disease Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Meningococcal Disease Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Meningococcal Disease Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Meningococcal Disease Drugs Sales Value by Application
  10. 5.3.1 Global Meningococcal Disease Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Meningococcal Disease Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Meningococcal Disease Drugs Sales Value Share by Application (2021-2032)
6 Meningococcal Disease Drugs Regional Sales and Value Analysis
  1. 6.1 Global Meningococcal Disease Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Meningococcal Disease Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Meningococcal Disease Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Meningococcal Disease Drugs Sales by Region (2027-2032)
  5. 6.3 Global Meningococcal Disease Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Meningococcal Disease Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Meningococcal Disease Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Meningococcal Disease Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Meningococcal Disease Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Meningococcal Disease Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Meningococcal Disease Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Meningococcal Disease Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Meningococcal Disease Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Meningococcal Disease Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Meningococcal Disease Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Meningococcal Disease Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Meningococcal Disease Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Meningococcal Disease Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Meningococcal Disease Drugs Sales Value Share by Country, 2025 VS 2032
7 Meningococcal Disease Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Meningococcal Disease Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Meningococcal Disease Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Meningococcal Disease Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Meningococcal Disease Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Meningococcal Disease Drugs Sales by Country (2027-2032)
  6. 7.4 Global Meningococcal Disease Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Meningococcal Disease Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Meningococcal Disease Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Meningococcal Disease Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Meningococcal Disease Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Meningococcal Disease Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Yiling Pharmaceutical
  2. 8.1.1 Yiling Pharmaceutical Company Information
  3. 8.1.2 Yiling Pharmaceutical Business Overview
  4. 8.1.3 Yiling Pharmaceutical Meningococcal Disease Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Yiling Pharmaceutical Meningococcal Disease Drugs Product Portfolio
  6. 8.1.5 Yiling Pharmaceutical Recent Developments
  7. 8.2 SSY Group Limited
  8. 8.2.1 SSY Group Limited Company Information
  9. 8.2.2 SSY Group Limited Business Overview
  10. 8.2.3 SSY Group Limited Meningococcal Disease Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 SSY Group Limited Meningococcal Disease Drugs Product Portfolio
  12. 8.2.5 SSY Group Limited Recent Developments
  13. 8.3 Apeloa Pharmaceutical Co.,Ltd.
  14. 8.3.1 Apeloa Pharmaceutical Co.,Ltd. Company Information
  15. 8.3.2 Apeloa Pharmaceutical Co.,Ltd. Business Overview
  16. 8.3.3 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
  18. 8.3.5 Apeloa Pharmaceutical Co.,Ltd. Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Meningococcal Disease Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Meningococcal Disease Drugs Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck Sharp & Dohme
  26. 8.5.1 Merck Sharp & Dohme Company Information
  27. 8.5.2 Merck Sharp & Dohme Business Overview
  28. 8.5.3 Merck Sharp & Dohme Meningococcal Disease Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck Sharp & Dohme Meningococcal Disease Drugs Product Portfolio
  30. 8.5.5 Merck Sharp & Dohme Recent Developments
  31. 8.6 Lukang Pharmaceutical Co.,Ltd.
  32. 8.6.1 Lukang Pharmaceutical Co.,Ltd. Company Information
  33. 8.6.2 Lukang Pharmaceutical Co.,Ltd. Business Overview
  34. 8.6.3 Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
  36. 8.6.5 Lukang Pharmaceutical Co.,Ltd. Recent Developments
  37. 8.7 Shandong Jincheng Pharmaceutical Group Co.,ltd.
  38. 8.7.1 Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information
  39. 8.7.2 Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview
  40. 8.7.3 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Product Portfolio
  42. 8.7.5 Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Meningococcal Disease Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Meningococcal Disease Drugs Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 North China Pharmaceutical Company Ltd.
  50. 8.9.1 North China Pharmaceutical Company Ltd. Company Information
  51. 8.9.2 North China Pharmaceutical Company Ltd. Business Overview
  52. 8.9.3 North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Product Portfolio
  54. 8.9.5 North China Pharmaceutical Company Ltd. Recent Developments
  55. 8.10 Hebei Hejia Pharmaceutical Technology Group Co., Ltd
  56. 8.10.1 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information
  57. 8.10.2 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview
  58. 8.10.3 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Product Portfolio
  60. 8.10.5 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Developments
  61. 8.11 Harbin Pharmaceutical Group Co.,Ltd.
  62. 8.11.1 Harbin Pharmaceutical Group Co.,Ltd. Company Information
  63. 8.11.2 Harbin Pharmaceutical Group Co.,Ltd. Business Overview
  64. 8.11.3 Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
  66. 8.11.5 Harbin Pharmaceutical Group Co.,Ltd. Recent Developments
  67. 8.12 GlaxoSmithKline
  68. 8.12.1 GlaxoSmithKline Company Information
  69. 8.12.2 GlaxoSmithKline Business Overview
  70. 8.12.3 GlaxoSmithKline Meningococcal Disease Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 GlaxoSmithKline Meningococcal Disease Drugs Product Portfolio
  72. 8.12.5 GlaxoSmithKline Recent Developments
  73. 8.13 Baiyunshan Pharmaceutical
  74. 8.13.1 Baiyunshan Pharmaceutical Company Information
  75. 8.13.2 Baiyunshan Pharmaceutical Business Overview
  76. 8.13.3 Baiyunshan Pharmaceutical Meningococcal Disease Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Baiyunshan Pharmaceutical Meningococcal Disease Drugs Product Portfolio
  78. 8.13.5 Baiyunshan Pharmaceutical Recent Developments
  79. 8.14 Sanofi Pasteur
  80. 8.14.1 Sanofi Pasteur Company Information
  81. 8.14.2 Sanofi Pasteur Business Overview
  82. 8.14.3 Sanofi Pasteur Meningococcal Disease Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Sanofi Pasteur Meningococcal Disease Drugs Product Portfolio
  84. 8.14.5 Sanofi Pasteur Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Meningococcal Disease Drugs Value Chain Analysis
  2. 9.1.1 Meningococcal Disease Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Meningococcal Disease Drugs Sales Mode & Process
  6. 9.2 Meningococcal Disease Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Meningococcal Disease Drugs Distributors
  9. 9.2.3 Meningococcal Disease Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst